Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11808755 | 0.85 | POLB (0.58) | MAPK1LMNAHTTPOLBMEN1 | |
| SCHEMBL566498 | 0.85 | POLB (0.70) | LMNAHTTPOLBMEN1KMT2A | |
| SCHEMBL8204769 | 0.85 | CREBBP (0.66) | MAPK1LMNAHTTPOLBMEN1 | |
| SCHEMBL1402177 | 0.84 | MAPK1 (0.84) | MAPK1LMNAHTTPOLBTSHR | |
| SCHEMBL6509070 | 0.84 | POLB (0.65) | LMNAHTTPOLBMEN1KMT2A | |
| Methylamine SCHEMBL5152509 | 0.83 | POLB (0.56) | MAPK1LMNAHTTPOLBMEN1 | |
| SCHEMBL4515986 | 0.83 | LMNA (0.50) | MAPK1LMNAHTTPOLBMEN1 | |
| SCHEMBL4687860 | 0.82 | MRGPRX4 (0.46) | MAPK1LMNAHTTTDP1KDM4E | |
| SCHEMBL1398536 | 0.82 | MEN1 (0.59) | LMNAPOLBMEN1KMT2AGAA | |
| SCHEMBL6508891 | 0.82 | LMNA (0.56) | MAPK1LMNAHTTPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1255752-B1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2007-01-11 | — | — | US | disclosed |
| US-7125905-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-7053114-B2 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050176802-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2005-08-11 | — | — | US | disclosed |
| EP-1427326-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN INC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| CN-1541098-A | Combination therapy for treatment of cancer | �ո��� | 2004-10-27 | — | — | CN | disclosed |
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2003-11-20 | — | — | US | disclosed |
| US-6573293-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. | 2003-06-03 | — | — | US | disclosed |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN. INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1255752-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | disclosed |
| WO-2002081466-A1 | PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES | SUGEN, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-1233943-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | Sugen, Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001060814-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-08-23 | — | — | WO | disclosed |
| WO-2001037820-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | SUGEN, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PTGS2, PTGES2, PTGFR | MAPK1 1014/4885LMNA 4272/4885HTT 3697/4885 |
| US-20050176802-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | MAPK1 246/4885LMNA 3333/4885HTT 2522/4885 |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | MAPK1 352/4885LMNA 2393/4885HTT 3768/4885 |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, PLK2, PNCK | MAPK1 237/4885LMNA 3259/4885HTT 2627/4885 |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | MAPK1 246/4885LMNA 3333/4885HTT 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.